# ![@NovartisNews Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1075773583220244480.png) @NovartisNews Novartis News

Novartis News posts on X about novartis, $nvs, $novn, media the most. They currently have [-----] followers and [--] posts still getting attention that total [--] engagements in the last [--] hours.

### Engagements: [--] [#](/creator/twitter::1075773583220244480/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1075773583220244480/c:line/m:interactions.svg)

- [--] Week [---] -44%
- [--] Month [-----] -100%
- [--] Months [---------] +4,366%
- [--] Year [---------] +8,953%

### Mentions: [--] [#](/creator/twitter::1075773583220244480/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1075773583220244480/c:line/m:posts_active.svg)

- [--] Months [--] +121%
- [--] Year [--] +700%

### Followers: [-----] [#](/creator/twitter::1075773583220244480/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1075773583220244480/c:line/m:followers.svg)

- [--] Week [-----] +0.02%
- [--] Month [-----] -0.06%
- [--] Months [-----] +0.01%
- [--] Year [-----] -0.11%

### CreatorRank: [---------] [#](/creator/twitter::1075773583220244480/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1075773583220244480/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  84.62% [currencies](/list/currencies)  3.08% [finance](/list/finance)  3.08% [travel destinations](/list/travel-destinations)  1.54%

**Social topic influence**
[novartis](/topic/novartis) #20, [$nvs](/topic/$nvs) 32.31%, [$novn](/topic/$novn) 24.62%, [media](/topic/media) 6.15%, [announces](/topic/announces) #608, [data](/topic/data) 6.15%, [social](/topic/social) 4.62%, [posts](/topic/posts) 4.62%, [release](/topic/release) 4.62%, [san diego](/topic/san-diego) 3.08%

**Top accounts mentioned or mentioned by**
[@usfda](/creator/undefined) [@asco](/creator/undefined) [@ehahematology](/creator/undefined) [@escardio](/creator/undefined) [@tourmalinebio](/creator/undefined)

**Top assets mentioned**
[Novartis AG (NVS)](/topic/novartis)
### Top Social Posts
Top posts by engagements in the last [--] hours

"#NVSQ425 Novartis social media posts on Q4 and Full-Year [----] results contain forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information. #NVSQ425 Novartis social media posts on Q4 and Full-Year [----] contain non-IFRS measures. An explanation of non-IFRS measures is available on our website Novartis quarterly financial results Novartis. $NVS $NOVN #NovartisNews https://twitter.com/i/web/status/2018927500248658166 https://twitter.com/i/web/status/2018927500248658166"  
[X Link](https://x.com/anyuser/status/2018927500248658166)  2026-02-04T06:00Z [----] followers, [---] engagements


"Novartis to break ground on its third Biomedical Research centera facility designed to provide world-class scientific infrastructure and expand its drug discovery capabilities in San Diego California https://go.novartis.social/4a7KTxq https://go.novartis.social/4a7KTxq"  
[X Link](https://x.com/NovartisNews/status/2019821888277737800)  2026-02-06T17:13Z [----] followers, [---] engagements


"Novartis announces Q4 [----] earnings. Learn more in our press release: #NovartisNews $NVS $NOVN #NVSQ42025 https://go.novartis.social/4adUtyW https://go.novartis.social/4adUtyW"  
[X Link](https://x.com/anyuser/status/2018931606568698262)  2026-02-04T06:16Z [----] followers, [---] engagements


"Novartis announces topline Phase III data over [---] years in IgA nephropathy. #kidneydisease #IgAN #NovartisNews #ProtectingKidneyTransformingCare https://go.novartis.social/4agpiUZ https://go.novartis.social/4agpiUZ"  
[X Link](https://x.com/NovartisNews/status/2022196543202172978)  2026-02-13T06:30Z [----] followers, [---] engagements


"Novartis delivers strong sales growth robust margin expansion and raises guidance. Announces USD [--] billion share buyback and Board endorses Sandoz spin-off. #NovartisNews $NVS $NOVN #NVSQ223"  
[X Link](https://x.com/NovartisNews/status/1681168628014522368)  2023-07-18T05:06Z [----] followers, [----] engagements


"Novartis delivers 12% sales and 21% core operating income growth from continuing operations (in cc1). Executes Sandoz spin-off achieves important innovation milestones and raises FY [----] guidance. #NovartisNews $NVS $NOVN #NVSQ323"  
[X Link](https://x.com/NovartisNews/status/1716682707059544329)  2023-10-24T05:07Z [----] followers, [---] engagements


"For #Investors and #Media Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR [--] per share or an aggregate of EUR 2.7bn in cash. $NVS $NOVN"  
[X Link](https://x.com/NovartisNews/status/1754630618250367186)  2024-02-05T22:18Z [----] followers, [----] engagements


"Novartis presents new positive long-term Phase III data for its BTK inhibitor in #CSU at #EAACI2024. Data will be submitted to global health authorities starting in H2 [----] #NovartisNews https://novartis.social/6011YcEmP https://novartis.social/6011YcEmP"  
[X Link](https://x.com/NovartisNews/status/1796318157524672514)  2024-05-30T23:09Z [----] followers, [---] engagements


"#NVSQ224 Novartis social media posts on Q2 [----] contain non-IFRS measures. An explanation of non-IFRS measures is available on our website $NVS $NOVN #NovartisNews https://go.novartis.social/3WcNMX1 https://go.novartis.social/3WcNMX1"  
[X Link](https://x.com/NovartisNews/status/1813811612194595162)  2024-07-18T05:42Z [----] followers, [---] engagements


"Novartis delivered strong operational performance and achieved key pipeline milestones in Q3 supporting further upgrade to FY24 guidance. #NovartisNews $NVS $NOVN #NVSQ324 https://go.novartis.social/4eYn0tB https://go.novartis.social/4eYn0tB"  
[X Link](https://x.com/NovartisNews/status/1851144686032830518)  2024-10-29T06:11Z [----] followers, [---] engagements


"#NVSQ324 Novartis social media posts on Q3 [----] contain non-IFRS measures. An explanation of non-IFRS measures is available on our website $NVS $NOVN #NovartisNews https://go.novartis.social/4e4fqfx https://go.novartis.social/4e4fqfx"  
[X Link](https://x.com/NovartisNews/status/1851152784168452355)  2024-10-29T06:43Z [----] followers, [---] engagements


"Data from the Phase III STEER study demonstrate clinically meaningful results in patients with #spinalmuscularatrophy aged two to [--] years. Read more: #NovartisNews https://go.novartis.social/41XEbHZ https://go.novartis.social/41XEbHZ"  
[X Link](https://x.com/NovartisNews/status/1873627143814656375)  2024-12-30T07:08Z [----] followers, [---] engagements


"Novartis continues strong momentum of sales growth with margin expansion reaches key innovation milestones in [----]. #NovartisNews $NVS $NOVN #NVSQ424 https://go.novartis.social/3WEy3Rm https://go.novartis.social/3WEy3Rm"  
[X Link](https://x.com/NovartisNews/status/1885211237610664034)  2025-01-31T06:19Z [----] followers, [---] engagements


"#NVSQ424 Novartis social media posts on Q4 and Full-Year [----] contain non-IFRS measures. An explanation of non-IFRS measures is available on our website: $NVS $NOVN #NovartisNews https://go.novartis.social/3Eij89f https://go.novartis.social/3Eij89f"  
[X Link](https://x.com/NovartisNews/status/1885219931932770724)  2025-01-31T06:53Z [----] followers, [---] engagements


"Novartis announces positive CHMP opinion for adult C3 glomerulopathy treatment (#C3G) #NovartisNews #ReimaginingMedicine https://go.novartis.social/4iit6q2 https://go.novartis.social/4iit6q2"  
[X Link](https://x.com/NovartisNews/status/1895459689426452809)  2025-02-28T13:03Z [----] followers, [---] engagements


"Novartis highlights commitment to hidradenitis suppurativa and chronic spontaneous urticaria at AAAAI and AAD annual congresses #NovartisNews https://go.novartis.social/3DkTQak https://go.novartis.social/3DkTQak"  
[X Link](https://x.com/NovartisNews/status/1895487119554138146)  2025-02-28T14:52Z [----] followers, [---] engagements


"Results from the Phase III STEER and Phase IIIb STRENGTH studies are being presented this week at the MDA Conference. Learn about the latest advancements in gene replacement therapy for #SpinalMuscularAtrophy: #NovartisNews https://go.novartis.social/4iYLMv9 https://go.novartis.social/4iYLMv9"  
[X Link](https://x.com/NovartisNews/status/1902355823042658339)  2025-03-19T13:45Z [----] followers, [---] engagements


"Novartis announces first-ever FDA approval in ultra-rare #kidneydisease #C3G #NovartisNews https://go.novartis.social/41HOnTj https://go.novartis.social/41HOnTj"  
[X Link](https://x.com/NovartisNews/status/1902995593074708646)  2025-03-21T08:07Z [----] followers, [---] engagements


"Novartis to share 7-year data in relapsing #multiplesclerosis and additional studies across neuroscience portfolio at #AANAM in San Diego. Learn more: #NovartisNews https://go.novartis.social/4hJ0i9u https://go.novartis.social/4hJ0i9u"  
[X Link](https://x.com/NovartisNews/status/1904504286840820169)  2025-03-25T12:03Z [----] followers, [---] engagements


"Novartis announces FDA approval of radioligand therapy for earlier use before chemotherapy in PSMA-positive metastatic prostate cancer (mCRPC) #NovartisNews https://go.novartis.social/4hMHSEF https://go.novartis.social/4hMHSEF"  
[X Link](https://x.com/NovartisNews/status/1905668197912600695)  2025-03-28T17:07Z [----] followers, [---] engagements


"Novartis announces FDA accelerated approval of treatment to reduce proteinuria in primary IgA nephropathy (#IgAN) https://go.novartis.social/4jkd1kb https://go.novartis.social/4jkd1kb"  
[X Link](https://x.com/NovartisNews/status/1907688013855129959)  2025-04-03T06:54Z [----] followers, [---] engagements


"Novartis announces Q1 [----] earnings. Learn more in our press release: #NovartisNews $NVS $NOVN #NVSQ12025 https://go.novartis.social/4juRB46 https://go.novartis.social/4juRB46"  
[X Link](https://x.com/NovartisNews/status/1917084780128309613)  2025-04-29T05:13Z [----] followers, [----] engagements


"#NVSQ12025 Novartis social media posts on Q1 [----] contain non-IFRS measures. An explanation of non-IFRS measures is available on our website. $NVS $NOVN #NovartisNews https://go.novartis.social/3Yof2no https://go.novartis.social/3Yof2no"  
[X Link](https://x.com/NovartisNews/status/1917088895952630092)  2025-04-29T05:29Z [----] followers, [---] engagements


"#NVSQ12025 Novartis social media posts on Q1 [----] earnings contain forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. $NVS $NOVN https://go.novartis.social/4iD25gu https://go.novartis.social/4iD25gu"  
[X Link](https://x.com/NovartisNews/status/1917092724789956853)  2025-04-29T05:44Z [----] followers, [---] engagements


"#News: Were excited to announce our upcoming oncology and hematology data that has been recently accepted at @ASCO Annual Meeting and @eha_hematology [----] Congress. #ASCO25 #EHA2025. https://go.novartis.social/4j9waoq https://go.novartis.social/4j9waoq"  
[X Link](https://x.com/NovartisNews/status/1923009219877535992)  2025-05-15T13:35Z [----] followers, [---] engagements


"At #ASCO25 we are presenting a new sub-analysis from the phase III NATALEE study in patients with HR+/HER2- early #breastcancer across age and menopausal status including younger patients #bcs https://novartis.social/6017SYcjl https://novartis.social/6017SYcjl"  
[X Link](https://x.com/NovartisNews/status/1929236530385633509)  2025-06-01T18:00Z [----] followers, [---] engagements


"#News: Phase III PSMAddition trial demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. https://go.novartis.social/4jzLY42 https://go.novartis.social/4jzLY42"  
[X Link](https://x.com/NovartisNews/status/1929414658655461619)  2025-06-02T05:47Z [----] followers, [---] engagements


"Novartis announces positive results from additional studies for the first and only oral monotherapy treatment in adults living with paroxysmal nocturnal hemoglobinuria (#PNH). #NovartisNews #EHA2025 https://go.novartis.social/4jLfGTu https://go.novartis.social/4jLfGTu"  
[X Link](https://x.com/NovartisNews/status/1933154067867738501)  2025-06-12T13:27Z [----] followers, [---] engagements


"Novartis receives approval for first malaria medicine for newborn babies and young infants. #NovartisNews https://go.novartis.social/3IkhbuZ https://go.novartis.social/3IkhbuZ"  
[X Link](https://x.com/NovartisNews/status/1942456918062293110)  2025-07-08T05:33Z [----] followers, [---] engagements


"Novartis announces Q2 [----] earnings. Learn more in our press release: #NovartisNews $NVS $NOVN #NVSQ22025 http://bit.ly/4lsfmLf http://bit.ly/4lsfmLf"  
[X Link](https://x.com/NovartisNews/status/1945712608495227288)  2025-07-17T05:10Z [----] followers, [---] engagements


"#NVSQ22025 Novartis social media posts on Q2 [----] contain non-IFRS measures. An explanation of non-IFRS measures is available on our website. $NVS $NOVN #NovartisNews https://go.novartis.social/4lREuee https://go.novartis.social/4lREuee"  
[X Link](https://x.com/NovartisNews/status/1945715902789369896)  2025-07-17T05:23Z [----] followers, [---] engagements


"#NVSQ22025 Novartis social media posts on Q2 [----] earnings contain forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. See our press release for details: $NVS $NOVN https://go.novartis.social/3GQCTX1 https://go.novartis.social/3GQCTX1"  
[X Link](https://x.com/NovartisNews/status/1945718595775799637)  2025-07-17T05:33Z [----] followers, [---] engagements


"Novartis announces global Phase III trials to demonstrate statistically significant reduction in disease activity for Sjgrens disease #NovartisNews https://go.novartis.social/4mwQUZ7 https://go.novartis.social/4mwQUZ7"  
[X Link](https://x.com/NovartisNews/status/1954789125170565201)  2025-08-11T06:17Z [----] followers, [---] engagements


"#News: Novartis reports positive Phase III VAYHIT2 results showing a statistically significant improvement in time to treatment failure in patients with primary ITP previously treated with corticosteroids #NovartisNews #ITP https://go.novartis.social/411LAVy https://go.novartis.social/411LAVy"  
[X Link](https://x.com/NovartisNews/status/1955142728356073628)  2025-08-12T05:42Z [----] followers, [---] engagements


"#News: Were excited to announce upcoming cardiovascular data that have been accepted at @escardio Congress. #ESCCongress https://go.novartis.social/4fPtb4w https://go.novartis.social/4fPtb4w"  
[X Link](https://x.com/NovartisNews/status/1957370578421326147)  2025-08-18T09:14Z [----] followers, [---] engagements


"At #ESCCongress we are presenting new data from the Phase IV V-DIFFERENCE study in patients with high cholesterol at high and very high cardiovascular risk. #Cardiology #HeartHealth #NoHeartLostTooSoon https://go.novartis.social/4oXsH06 https://go.novartis.social/4oXsH06"  
[X Link](https://x.com/NovartisNews/status/1961813880755388818)  2025-08-30T15:30Z [----] followers, [---] engagements


"Novartis presents new #RMS data at #ECTRIMS2025 including efficacy after switching from oral DMTs as well as 7-year efficacy and safety. Read more: #NovartisNews http://bit.ly/48v8Lfd http://bit.ly/48v8Lfd"  
[X Link](https://x.com/NovartisNews/status/1970757961178898700)  2025-09-24T07:51Z [----] followers, [---] engagements


"Novartis to unveil transformative data in advanced prostate and early breast cancer at #ESMO2025 #Oncology #CancerResearch #NovartisNews http://bit.ly/487SVr3 http://bit.ly/487SVr3"  
[X Link](https://x.com/NovartisNews/status/1971519283869147204)  2025-09-26T10:16Z [----] followers, [---] engagements


"#News: Novartis announces @US_FDA approval of a new oral targeted therapy for #ChronicSpontaneousUrticaria (#CSU). #NovartisNews https://go.novartis.social/4n2fn8R https://go.novartis.social/4n2fn8R"  
[X Link](https://x.com/NovartisNews/status/1973129068750176600)  2025-09-30T20:53Z [----] followers, [---] engagements


"#NVSQ32025 Novartis social media posts on Q3 [----] earnings contain forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. See our press release for details: $NVS $NOVN https://go.novartis.social/47x7gLz https://go.novartis.social/47x7gLz"  
[X Link](https://x.com/anyuser/status/1983058243925504346)  2025-10-28T06:28Z [----] followers, [---] engagements


"#News: Today we are announcing plans to build a flagship manufacturing hub in North Carolina US. This hub is expected to create [---] new jobs in the state and will expand end-to-end manufacturing capabilities across all our therapeutic areas in the US. 🔗 Read more about our investment: https://go.novartis.social/4i8TF1K https://go.novartis.social/4i8TF1K"  
[X Link](https://x.com/anyuser/status/1991218248361103541)  2025-11-19T18:53Z [----] followers, [---] engagements


"#News: The @US_FDA approved a new therapy for children two years and older teens and adults living with #SpinalMuscularAtrophy (SMA). #NovartisNews https://go.novartis.social/4oSLj0W https://go.novartis.social/4oSLj0W"  
[X Link](https://x.com/anyuser/status/1993107311162716509)  2025-11-24T23:59Z [----] followers, [---] engagements


"Novartis data underscore pioneering scientific innovation in hematology and oncology at #ASH25 and #SABCS25 #NovartisNews https://novartis.social/6014tnYre https://novartis.social/6014tnYre"  
[X Link](https://x.com/anyuser/status/1993208561870975228)  2025-11-25T06:42Z [----] followers, [---] engagements


"#News: Novartis builds fourth US radioligand therapy manufacturing facility in Winter Park Florida to optimize delivery of time-sensitive therapies. #NovartisNews https://go.novartis.social/4pwnkUY https://go.novartis.social/4pwnkUY"  
[X Link](https://x.com/anyuser/status/2009653900257710198)  2026-01-09T15:50Z [----] followers, [---] engagements


"Novartis Voyager Therapeutics reach license option agreement for target-specific access to next-generation AAV capsids for gene therapy application in rare neurological diseases. #NovartisNews"  
[X Link](https://x.com/NovartisNews/status/1501096796487045120)  2022-03-08T07:25Z [----] followers, [--] engagements


"#NVSQ223 Novartis tweets on Q2 [----] contain non-IFRS measures. An explanation of non-IFRS measures is available on our website $NVS $NOVN #NovartisNews https://bit.ly/3Q1CHGz https://bit.ly/3Q1CHGz"  
[X Link](https://x.com/NovartisNews/status/1681171421911822336)  2023-07-18T05:17Z [----] followers, [---] engagements


"Novartis has agreed to acquire Regulus Therapeutics a clinical-stage biopharmaceutical company focused on developing microRNA therapeutics with a focus on autosomal dominant polycystic kidney disease (ADPKD) a severe renal disease. For more information and cautionary statements: https://go.novartis.social/4jD4fy8 https://go.novartis.social/4jD4fy8"  
[X Link](https://x.com/NovartisNews/status/1917563136942694909)  2025-04-30T12:54Z [----] followers, [---] engagements


"Novartis has agreed to acquire @TourmalineBio a clinical-stage biopharmaceutical company focused on developing medicines that improve the lives of patients with life-altering immune and inflammatory diseases including a treatment option for ASCVD. For more information and cautionary statements: https://go.novartis.social/4gdWm1n https://go.novartis.social/4gdWm1n"  
[X Link](https://x.com/NovartisNews/status/1965292314869334264)  2025-09-09T05:52Z [----] followers, [---] engagements


"Novartis announces topline Phase III data over two years in IgAN #kidneydisease #igan #NovartisNews https://go.novartis.social/46RSTT4 https://go.novartis.social/46RSTT4"  
[X Link](https://x.com/NovartisNews/status/1978699174150365328)  2025-10-16T05:47Z [----] followers, [---] engagements


"#News: CHMP issues positive opinion for #Novartis treatment in newly diagnosed chronic myeloid leukemia based on Phase III data showing superior efficacy and favorable tolerability versus current first-line therapies #NovartisNews https://go.novartis.social/4ou1x06 https://go.novartis.social/4ou1x06"  
[X Link](https://x.com/NovartisNews/status/1979158399767187850)  2025-10-17T12:11Z [----] followers, [---] engagements


"At #ESMO25 we're presenting 5-year results from the pivotal NATALEE trial investigating a broad population of patients with HR+/HER2- early breast cancer. #NovartisNews https://go.novartis.social/48vEuNy https://go.novartis.social/48vEuNy"  
[X Link](https://x.com/NovartisNews/status/1979161974136090814)  2025-10-17T12:26Z [----] followers, [---] engagements


"Patients with metastatic hormone-sensitive prostate cancer show significant improvement in radiographic progression-free survival in Phase III PSMAddition trial #NovartisNews #reimaginingmedicine http://bit.ly/4oqxKFl http://bit.ly/4oqxKFl"  
[X Link](https://x.com/NovartisNews/status/1979924166926307579)  2025-10-19T14:54Z [----] followers, [---] engagements


"Novartis announces positive Phase III results in polymyalgia rheumatica (PMR). Study met primary and all secondary endpoints showing sustained remission and reduced steroid use through Week [--]. #Rheumatology #Immunology #NovartisNews https://go.novartis.social/4olX28d https://go.novartis.social/4olX28d"  
[X Link](https://x.com/NovartisNews/status/1980872494576808281)  2025-10-22T05:43Z [----] followers, [---] engagements


"Novartis highlights commitment to scientific innovation at #ACRConvergence [----] with data presentations in Sjogren's disease and systemic lupus erythematosus. #ACR2025 #NovartisNews https://go.novartis.social/4qqgthd https://go.novartis.social/4qqgthd"  
[X Link](https://x.com/NovartisNews/status/1982110547173675478)  2025-10-25T15:42Z [----] followers, [---] engagements


"Novartis presents new Phase III study data in Sjogren's at #ACR25 showing promising potential to reduce disease activity and patient burden. #Rheum https://go.novartis.social/3Lxefwy https://go.novartis.social/3Lxefwy"  
[X Link](https://x.com/anyuser/status/1983548940541940035)  2025-10-29T14:58Z [----] followers, [---] engagements


"Novartis announces new data at ASN #KidneyWk and #AHA25 highlighting commitment to its cardiovascular renal and metabolic disease portfolio. #NovartisNews https://novartis.social/6018tG0es https://novartis.social/6018tG0es"  
[X Link](https://x.com/anyuser/status/1985599166685323697)  2025-11-04T06:45Z [----] followers, [---] engagements


"Today our leadership team is holding our Meet Novartis Management event for investors and analysts in London. We announced that we rolled forward our mid-term guidance and highlighted our robust pipeline to drive sustainable growth. Learn more here: #NovartisNews $NVS $NOVN #ReimaginingMedicine https://novartis.social/6017tTDqV https://novartis.social/6017tTDqV"  
[X Link](https://x.com/anyuser/status/1991397598578569233)  2025-11-20T06:46Z [----] followers, [---] engagements


"Missed yesterdays Meet Novartis Management event that captured how we will sustain momentum over the long term Watch the replay here: #NovartisNews $NVS $NOVN #ReimagineMedicine https://novartis.social/6017tT7cV https://novartis.social/6017tT7cV"  
[X Link](https://x.com/anyuser/status/1991854106705580464)  2025-11-21T13:00Z [----] followers, [---] engagements


"#News: Patients with primary immune thrombocytopenia experienced extended disease control in Phase III VAYHIT2 trial #NovartisNews #reimaginingmedicine #ASH25 https://novartis.social/6010t9kmw https://novartis.social/6010t9kmw"  
[X Link](https://x.com/anyuser/status/1998381366682009724)  2025-12-09T13:17Z [----] followers, [---] engagements


"Novartis announces Q3 [----] earnings. Learn more in our press release: #NovartisNews $NVS $NOVN #NVSQ32025 https://go.novartis.social/498lHID https://go.novartis.social/498lHID"  
[X Link](https://x.com/anyuser/status/1983053130884358466)  2025-10-28T06:08Z [----] followers, [---] engagements


"#NVSQ32025 Novartis social media posts on Q3 [----] contain non-IFRS measures. An explanation of non-IFRS measures is available on our website. $NVS $NOVN #NovartisNews https://go.novartis.social/47KGfWb https://go.novartis.social/47KGfWb"  
[X Link](https://x.com/anyuser/status/1983055279018144095)  2025-10-28T06:16Z [----] followers, [---] engagements


"Novartis has reached an agreement with the US government that aims to lower the price of innovative medicines in the US and support continued US investment in manufacturing and research and development #NovartisNews https://novartis.social/6013tUMGl https://novartis.social/6013tUMGl"  
[X Link](https://x.com/anyuser/status/2002103388234748315)  2025-12-19T19:46Z [----] followers, [---] engagements


"Novartis investigational treatment receives FDA Breakthrough Therapy designation in Sjgrens disease. #NovartisNews #SjgrensDisease #ReimaginingMedicine https://novartis.social/6015tCWk9 https://novartis.social/6015tCWk9"  
[X Link](https://x.com/anyuser/status/2012211437163175939)  2026-01-16T17:12Z [----] followers, [---] engagements


"Novartis has entered into an agreement to acquire Avidity a San Diego-based publicly traded biopharmaceutical company committed to delivering a new class of therapeutics enabling RNA delivery to muscle called Antibody Oligonucleotide Conjugates (AOCs) for serious genetic neuromuscular diseases. For more information and cautionary statements: https://go.novartis.social/47lF3Y0 https://go.novartis.social/47lF3Y0"  
[X Link](https://x.com/anyuser/status/1982499697362342213)  2025-10-26T17:28Z [----] followers, [----] engagements


"This #SABCS25 we're advancing the conversation on #breastcancer care. From metastatic to early-stage disease we're presenting long-term data that adds to evidence across a broad range of breast cancer patients🔗 Learn more: https://novartis.social/6011t9kwh https://novartis.social/6011t9kwh"  
[X Link](https://x.com/anyuser/status/1998380107182854288)  2025-12-09T13:12Z [----] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing